Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Edge Medical eyes Mainland listing months after Hong Kong IPO
Surgical robot maker Shenzhen Edge Medical Co. Ltd. (2675.HK) announced last Friday that it is exploring a second listing on China’s domestic A-share markets in Shanghai and Shenzhen, just months…
Burning Rock’s revenue dips on weakness in R&D, central lab businesses
Cancer testing company Burning Rock Biotech Ltd. (BNR.US) on Thursday reported its revenue fell 9.3% year-on-year to 135 million yuan ($20.1 million) in the second quarter, as an increase for…
Medcaptain plunges in trading debut for heavily oversubscribed IPO
Medical device maker Shenzhen Medcaptain Technology Co. Ltd. (2041.HK) plunged in its Hong Kong trading debut on Monday, opening 35% lower before stabilizing to close at HK$10.10 by the midday…
Jinxin Fertility swings back to the black as margins improve and U.S. unit gains traction
The assisted reproduction services provider posted a net profit of 110 million yuan in the first half of 2026, as its revenue rose 6.6% By Teri Yu Jinxin Fertility Group…
China pivots to ‘hard tech’ and global branding: Frost & Sullivan Summit
As global trade becomes fragmented, Chinese enterprises are embracing hard technology and non-market strategies to build durable, world-class brands By Da Cheung Chinese enterprises are adapting to a shifting global…
MicroPort Scientific’s revenue rises up to 14% on strong export growth
Medical device maker MicroPort Scientific Corp. (0853.HK) said on Wednesday its revenue rose between 12% and 14% in the first half of this year, lifted by triple-digit growth for its…
Recent Articles
RELATED ARTICLES
-
Legend Bio CEO resigns, shares tumble
- BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
iQiyi names Tian Ying as new CFO
IQ.US
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Cancer screening company faces tough IPO test as market cools
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
